ArticleInternational ophthalmology2026
Choroidal thickness changes in patients with systemic lupus erythematosus treated with hydroxychloroquine using three dimensional maps.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare variations in choroidal thickness (CT) between patients with systemic lupus erythematosus (SLE) treated with hydroxychloroquine (HCQ) and healthy subjects for at least one year.
methodsCross-sectional study enrolling patients between 30 and 55 years of age with SLE and treated with HCQ for at least one year, and aged-matched healthy subjects. Exclusion criteria included any other ophthalmological disorder or previous treatment, and systemic treatment with immunosuppressive drugs or a dose of corticosteroids higher than 5 mg/d. Macular CT was measured automatically in a grid of 30 × 30 cubes using Triton swept-source optical coherence tomography (Topcon). These were merged into 25 zones (each one comprising 6 × 6 cubes). Three-dimensional (3D) CT maps were created using Microsoft Excel and mean CT values in the grid of 30 × 30 cubes. One eye of each patient was randomly selected for the study.
results60 patients and 54 healthy subjects were recruited. Mean age was 45.16 ± 6.43 and 43.79 ± 8.98 years (p = 0.346), respectively. Mean axial length was 23.52 ± 0.96 and 23.67 ± 0.87 mm (p = 0.137), respectively. Mean SLE duration was 125.58 ± 63.10 months, and mean duration of HCQ was 87.87 ± 52.13 months. There were no differences in intraocular pressure (p = 0.271) or spherical equivalent (p = 0.219). Choroidal zones number 9, 14, 15, 19 and 20 (central nasal locations) were thicker in SLE patients. Neither SLE duration, nor HCQ duration had any influence on CT (p > 0.05).
conclusionsPatients with SLE treated with HCQ for one or more years present higher CT values than healthy subjects. Nasal zones seem to be the most sensitive to these changes, while the other choroidal locations remain similar apparently. However, neither duration of SLE nor duration or dose of HCQ treatment seemed to have any influence on CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.